Navigation Links
Key milestone towards the development of a new clinically useful antibiotic
Date:7/12/2010

Scientists have identified the genes necessary for making a highly potent and clinically unexploited antibiotic in the fight against multi-resistant pathogens.

"Lantibiotics are antibiotic molecules produced by soil bacteria, and we are studying probably the most potent one known, microbisporicin, which is active against many different pathogens," said Professor Mervyn Bibb from the John Innes Centre, co-author on the paper to be published in PNAS.

"Our study has allowed us to understand how the antibiotic is made by a bacterium that was first isolated from Indonesian soil. Now we can engineer the bacterium to make similar but better molecules, and lots of them."

"For example, we can take rational approaches to improve its pharmacological properties, such as its stability in the blood stream and how it distributes into tissues."

The producing bacterium, Microbispora corallina, is difficult to work with. It grows very slowly and no tools existed for its genetic manipulation. PhD student Lucy Foulston developed the tools herself. She then took advantage of new developments in genome sequencing to identify and then isolate the M. corallina gene cluster responsible for microbisporicin production.

This allowed her to analyse how the bacterium makes the molecule and the functions of the genes involved. Notably, she was able to identify the genes responsible for giving microbisporicin some of its unique features.

The antibiotic molecule binds to a well established target in the pathogenic bacteria it kills, and as yet there are no signs of resistance towards it.

Microbisporicin is very effective at killing disease-causing bacteria, including Clostridium difficile, methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin resistant pathogens.

"This molecule is already in late preclinical-phase trials and in animal models has shown to be more effective than the current drugs of last resort, linezolid and vancomycin," said Professor Bibb.

"We believe that this study will make a major contribution to the future clinical development of this exciting antibiotic, and the derivatives that can be made using the knowledge and technology that we have developed."


'/>"/>

Contact: Zoe Dunford
zoe.dunford@bbsrc.ac.uk
44-160-325-5111
Norwich BioScience Institutes
Source:Eurekalert

Related biology technology :

1. RSB Spine, LLC, Announces Record Second-Quarter 2010 Revenue and Monthly Sales Milestone
2. NeoStem Achieves New Milestone as Company Joins Russell 3000 Index
3. Copan Installs Milestone 30th Walk-Away Specimen Processor (WASP)
4. Xofts Electronic Brachytherapy Hits Milestone With 10 New Skin Cancer Installations
5. Ten Million Flex-Fuel Vehicles in Brazil a Milestone that Deserves Global Dissemination by Automakers
6. Advanced Life Sciences Previews 2010 Milestones
7. Endo and Jubilant Expand Oncology Discovery Partnership on Successful Delivery of Early Milestone
8. Microbix Pipeline Set To Reach Milestones In 2010
9. BioSoteria Drug Safety Newsletter Reaches Milestone
10. Gen-Probe to Acquire Prodesse, Leader in Molecular Testing for Respiratory Infectious Diseases, for $60 Million in Cash Plus Potential Milestone Payments
11. Major Milestone Achieved - Berlin Heart EXCOR Pediatric IDE Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... 5, 2016 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or ... Data and Safety Monitoring Board (DSMB) for the ... disease (CVD) patients has completed a second planned ... continue as planned without any modifications. The DSMB ... safety or efficacy concerns were identified. The DSMB ...
(Date:12/5/2016)... , Dec 5, 2016 Research ... report "DNA Sequencing - Technologies, Markets and Companies" ... ... report briefly reviews basics of human genome variations, development of ... are described as well as companies developing them. Various applications ...
(Date:12/4/2016)... ... December 03, 2016 , ... ... studies. A microbiome impact grant award has been made to Dr. Renato Polimanti ... smoking and drinking on the oral microbiome. Grant proposals have been vetted by ...
(Date:12/2/2016)... ... December 02, 2016 , ... In ... cervical and lumbar disc production, company President, Jake Lubinski will be traveling to ... the AxioMed disc in Bern, Lucerne, and Zurich to discuss the benefits of ...
Breaking Biology Technology:
(Date:12/6/2016)... 2016 Securus Technologies, a leading provider ... public safety, investigation, corrections and monitoring, and the ... five (5) year funding commitment by Securus to ... rehabilitation and reentry support to more inmates and ... 2004, the Prison Entrepreneurship Program (PEP) is an ...
(Date:11/30/2016)... Poland , Nov. 30, 2016 Not many of us realize that ... aspects of recovery so we need to do it well. Inadequate sleep levels have ... high blood pressure, stroke, diabetes, and even cancer. Maybe now is the ... present that could help them to manage their sleep quality? ... ...
(Date:11/29/2016)... CANNES, France , November 29, 2016 Nearly ... Continue Reading ... ... System is part of an efficient Identity Management. (PRNewsFoto/DERMALOG Identification Systems) ... DERMALOG is Germany's largest Multi-Biometric ...
Breaking Biology News(10 mins):